# Serum Cholinesterases, Paraoxonase, and Cardiovascular Risk After Intravitreal Bevacizumab

> **NCT07550777** · — · RECRUITING · sponsor: **Ataturk University** · enrollment: 180 (estimated)

## Conditions studied

- Diabete Mellitus
- Retina Vein Occlusion
- Age Macular Degeneration

## Interventions

- **PROCEDURE:** blood test

## Key facts

- **NCT ID:** NCT07550777
- **Lead sponsor:** Ataturk University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-03
- **Primary completion:** 2026-06-10
- **Final completion:** 2026-07-10
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07550777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07550777, "Serum Cholinesterases, Paraoxonase, and Cardiovascular Risk After Intravitreal Bevacizumab". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07550777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*